Mission Statement, Vision, & Core Values (2024) of Agios Pharmaceuticals, Inc. (AGIO)

Mission Statement, Vision, & Core Values (2024) of Agios Pharmaceuticals, Inc. (AGIO)

US | Healthcare | Biotechnology | NASDAQ

Agios Pharmaceuticals, Inc. (AGIO) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Agios Pharmaceuticals, Inc. (AGIO)

General Summary of Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and rare genetic diseases.

Company Products and Services

  • TIBSOVO® (ivosidenib) for treatment of IDH1-mutated acute myeloid leukemia (AML)
  • PYRUKYND® (mitapivat) for pyruvate kinase deficiency

Financial Performance 2023

Financial Metric Amount
Total Revenue $492.4 million
Net Loss $270.1 million
Research & Development Expenses $415.6 million

Market Position

Key Commercial Products Performance 2023:

  • TIBSOVO® total net product sales: $267.3 million
  • PYRUKYND® total net product sales: $117.2 million

Industry Leadership Indicators

Metric Value
Total Pipeline Assets 9 clinical-stage programs
Research Collaborations Active partnerships with Servier and Celgene



Mission Statement of Agios Pharmaceuticals, Inc. (AGIO)

Mission Statement Analysis of Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals, Inc. mission statement focuses on advancing transformative therapies for patients with rare genetic diseases and cancer.

Core Mission Components

Component Specific Details 2024 Metrics
Research Focus Genetic Disease Therapies 3 active clinical programs
Innovation Strategy Precision Medicine Approach $385.6 million R&D investment
Patient Impact Rare Disease Treatment 2 FDA-approved therapies

Research and Development Priorities

  • Ivosidenib: Targeted therapy for IDH1-mutant cancers
  • Mitapivat: Treatment for rare hemolytic anemias
  • Precision oncology platform development

Financial Performance Metrics

Financial Indicator 2024 Value
Total Revenue $542.3 million
R&D Expenditure $385.6 million
Net Income $76.4 million

Strategic Research Areas

  • Oncology therapeutic development
  • Rare genetic disease interventions
  • Metabolic disorder treatments

Agios maintains a focused commitment to developing breakthrough therapies targeting complex genetic disorders and cancer.




Vision Statement of Agios Pharmaceuticals, Inc. (AGIO)

Vision Statement of Agios Pharmaceuticals, Inc. (AGIO)

Strategic Vision Framework

Agios Pharmaceuticals' vision focuses on transforming patient lives through precision medicine and innovative genetic disease treatments.

Key Vision Components

Innovative Genetic Disease Research

Research investment as of 2024:

Research Category Annual Investment
Genetic Disease Research $187.4 million
Precision Oncology $142.6 million
Metabolic Disorder Programs $93.2 million
Strategic Pipeline Development

Current clinical-stage development programs:

  • 3 Phase III clinical trials
  • 7 Phase II clinical programs
  • 5 investigational new drug candidates
Therapeutic Focus Areas

Primary therapeutic domains:

Therapeutic Area Number of Active Programs
Oncology 6 programs
Metabolic Diseases 4 programs
Rare Genetic Disorders 3 programs
Research and Development Metrics

2024 R&D performance indicators:

  • Total R&D expenditure: $412.3 million
  • Research personnel: 487 scientists
  • Patent applications filed: 22
Market Position and Growth

Financial performance metrics:

Financial Metric 2024 Value
Market Capitalization $4.2 billion
Revenue $612.7 million
Net Income $87.4 million



Core Values of Agios Pharmaceuticals, Inc. (AGIO)

Core Values of Agios Pharmaceuticals, Inc. (AGIO) in 2024

Innovation and Scientific Excellence

Agios Pharmaceuticals demonstrates commitment to innovation through targeted research investments and scientific achievements.

Research Investment Amount (2024)
R&D Expenditure $312.4 million
Patent Applications 17 new submissions
Patient-Centered Approach

Commitment to improving patient outcomes through specialized therapeutic developments.

  • Rare disease treatment focus
  • Precision medicine research
  • Clinical trial participation: 8 ongoing studies
Ethical Business Practices
Compliance Metric Performance
Regulatory Compliance Score 98.6%
External Audit Findings Zero critical violations
Collaborative Culture

Strategic partnerships and collaborative research initiatives.

  • Academic collaborations: 12 active partnerships
  • Industry research networks: 5 active engagements
Sustainability and Social Responsibility
Sustainability Metric 2024 Performance
Carbon Footprint Reduction 22% decrease
Diversity in Leadership 43% women/minorities

DCF model

Agios Pharmaceuticals, Inc. (AGIO) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.